SpringWorks Therapeutics (SWTX) Q2 2024 earnings summary

Executive summary

• OGSIVEO generated $40.2 million in Q2 2024 net product revenue, with $61.2 million for the first half of 2024, reflecting strong demand and rapid adoption as the standard of care for desmoid tumors in the U.S.

• NDA for mirdametinib in NF1-PN was submitted to the FDA, targeting both pediatric and adult populations, with regulatory approval and commercial launch anticipated in 2025 in the U.S. and Europe.

• The company is advancing a diversified pipeline, including trials in ovarian granulosa cell tumors, multiple myeloma, Hippo-mutant solid tumors, SW-682, and brimarafenib.

• Positive clinical data for OGSIVEO and mirdametinib were presented at major medical meetings, and OGSIVEO is the most prescribed systemic therapy for adults with desmoid tumors.

• Collaborations with BeiGene and MapKure support pipeline expansion and R&D activities.

Financial highlights

• Q2 2024 total revenue was $59.7 million, including $40.2 million net product revenue and $19.5 million from GSK deferred revenue recognition.

• Net loss for Q2 2024 was $39.9 million ($0.54/share), improved from $77.9 million ($1.25/share) in Q2 2023.

• Operating expenses increased year-over-year, driven by commercial activities for OGSIVEO and anticipated mirdametinib launch.

• Cash, cash equivalents, and marketable securities totaled $521.9 million as of June 30, 2024.

• Working capital was $376.8 million as of June 30, 2024.

Outlook and guidance

• Focus for H2 2024 includes driving broader OGSIVEO adoption, preparing for mirdametinib launch, and advancing European regulatory processes.

• Expectation of continued OGSIVEO growth, with expansion into new geographies and anticipation of European Commission approval in 2025.

• Long-term follow-up data from DeFi and initial data from ovarian granulosa cell tumor trial expected later this year.

• MAA submission for mirdametinib in EU planned for H2 2024; additional brimarafenib data expected in H1 2025.

• Management estimates current liquidity will fund operations for at least twelve months after the report date.